





















« mycoides cluster »








‐ Sub‐Saharan Africa mostly
‐ Recent introductions (Gabon, Congo)









Steps and strategies to control/eradicate CBPP and CCPP
Evaluate distribution and economic impact
Choose a realistic objective and time‐frame






























Zoning and movement control 
Mortality 
He1•ds Ol'indlvlduals 




Correct ly lmplemented 
Susceptible 
Vaccination 









































Very often « less than optimal »
Very often « less than optimal »
‐ Vaccination of infected animals!
‐ Improper diluents
‐ Too many doses per vial (small herds)
CBPP: no regular sero‐conversion
CCPP: no serological tool










































Experimental trial of an inactivated CBPP vaccine
Production of the antigen and inactivation at CIRAD
Preparation of an oil‐emulsion at SEPPIC

























That were shown to be infected by mycoplasmas
Of the mycoides cluster but not by Mccp
Distribution of PI values in Ethiopian goat herds
In a region where CCPP is enzootic (Afar depression)
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Validation of sero‐conversion after CCPP vaccination with AU‐PANVAC
‐ Production of  a reference CCPP vaccine batch (CIRAD)
‐ Vaccination of goats with various amounts of antigen and adjuvant (PANVAC)
‐ cELISA testing (CIRAD)
There is a correlation between sero‐conversion intensity and Antigen or Adjuvant quantities





CBPP and CCPP have been eradicated from zones, countries or continents in the past
They persist today in many countries (Africa mostly) and their distribution is expanding
Massive slaughter of infected animals or herds may not be socially acceptable any more
Prudent use of antibiotics may control these diseases, however
‐ Most probably, antibiotics alone will not lead to eradication
‐ There is a global trend to reduce the use of antibiotics (WHO, FAO, OIE) as
antibioresistance is certainly the most fearful threat for human health
Antibiotics could be used in combination with vaccines in « cost‐effective » strategies
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Conclusions and perspectives 2/2
Vaccination implementation is very often not satisfactory
‐ Vaccines are very often not quality controlled
‐ There are very few incentives for the proper implementation of vaccination
Lack of national funds
Lack of international incentives (contrarilly to FMD and PPR)
Vaccinations must be implemented within a logical framework
‐ Within countries, thanks to epidemiological analysis
‐ At a regional (trans‐national) level
Vaccines can and must be improved
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Thanks for your attention
Thanks to all the colleagues
that contributed to these
results, within the VACNADA
project or elsewhere
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